Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

Authors


  • ASSURANCESThe database was retained by the sponsor, but the investigators had access to the complete database. The statistical analyses were performed by the sponsoring company’s statistician and reviewed and approved by all authors. The authors assume full responsibility for the completeness and accuracy of the content of the manuscript. This clinical trial was registered on clinicaltrials.gov with registration number: NCT00384930

Lars Viktrup, Senior Medical Advisor, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285, USA.e-mail: viktrupla@lilly.com

Abstract

Study Type – Therapy (RCT)
Level of Evidence 1b

OBJECTIVE

To determine, by post hoc analysis, the effects of tadalafil (a long-acting phosphodiesterase 5 inhibitor) on peak urinary flow (Qmax), bladder capacity, voiding efficiency and the obstructive symptoms of benign prostatic hyperplasia (BPH) in men with lower urinary tract symptoms secondary to BPH (BPH-LUTS), compared with placebo.

PATIENTS AND METHODS

After a 4-week placebo run-in period, 1058 men with BPH-LUTS were randomly allocated to receive once daily treatment with placebo or tadalafil (2.5, 5, 10, or 20 mg) for 12 weeks. Uroflowmetry, postvoid residual volume (PVR), and BPH symptom score measurements were assessed throughout the trial.

RESULTS

Increases in Qmax were numerically greater for tadalafil (2.5, 5, 10, and 20 mg with percentage changes of 15%, 16%, 17%, 22%, respectively) vs placebo (12%), but did not reach statistical significance. Age, baseline Qmax, erectile dysfunction history, sexual activity, and previous α-blocker therapy significantly influenced the Qmax response. Tadalafil was not associated with significant changes in PVR. Tadalafil had its greatest effects on bladder capacity and voiding efficiency in men with a Qmax of <10 mL/s at baseline, but these changes were not significantly different from placebo responses. Tadalafil treatment significantly improved the IPSS obstructive subscores (tadalafil 2.5, 5, 10, 20 mg with percentage changes of 24%, 31%, 33%, 33%, respectively) vs placebo (13%).

CONCLUSIONS

Once daily tadalafil did not significantly change Qmax or voiding efficiency compared with placebo in men with BPH-LUTS, although there were dose-dependent improvements. No subgroups were identified where tadalafil or placebo treatment had a deleterious effect on Qmax. Despite these minimal changes in uroflowmetric measures, tadalafil was associated with clinically meaningful and statistically significant improvements in the obstructive symptoms of BPH.

Ancillary